Renhe Pharmaceutical: As of the end of July, a total of 96.2253 million yuan has been spent on share buybacks.

Renhe Pharmaceutical announced that the company decided in April 2026 to repurchase part of the publicly held shares for 80 million to 150 million yuan, intended for equity incentives or employee share ownership plans, with a repurchase price not exceeding 8 yuan per share. As of July 31, a total of 17,000,100 shares have been repurchased, accounting for 1.2143% of the total share capital, with the highest transaction price at 5.73 yuan per share and the lowest transaction price at 4.86 yuan per share, totaling an expenditure of 96,225,300 yuan. The repurchase will continue based on market conditions, with timely disclosures to follow.